Jefferies Backs Relmada, BTIG Turns Bullish on Invivyd
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
/ 2 items
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Invivyd is developing VYD2311, a non-vaccine antibody, to prevent COVID. Two key trials (DECLARATION/LIBERTY) will test its safety and effectiveness vs. placebo and mRNA vaccines, aiming to offer a flexible new choice for protection.